Iodine-124 (124I) can be used in a variety of PET applications, such as protein and antibody iodinations, as well as in the design and synthesis of new PET tracers. Scientists have recently instigated a significant amount of new research into 124I, owing to its promising features for PET [1][2]: it has a conveniently long half-life (t½ = 4.2 d), and knowledge of its labeling chemistry is well-established [1][3]. This makes 124I the perfect tool for extended radiosynthesis protocols and longitudinal PET imaging studies. Quite a number of long-term pharmacokinetic studies are now using 124I. The result is a highly innovative field of research, in which numerous novel therapies — using large biomolecules, nanoparticles, or further drug delivery systems — are currently being proposed [3].

If you have any questions, do not hesitate to contact our Product Specialist, Renske Raaphorst. You can reach her at:
Tel: +31 20 4444380

  • Packaging: 2.0 mL V-bottom screw top glass vials.
  • Availablity: Dispensed every Monday.
  • Delivery Service: Cyclotron cooperates closely with PerkinElmer for the distribution of the radionuclide 124I.
  • Material Safety Data Sheet (MSDS)

Fact Sheet Iodine-124 radiochemical

Fact Sheet: Iodine-124 radiochemicalDownload

Process Data
Nuclear reaction 124Te(p,n)124I
Chemical processing Dry distillation of iodine from an activated target into an alkaline solution
Assay Gamma-ray spectrometry – the most prominent gamma photon has an energy of 603 keV

Product specifications
Chemical form 124I as iodide in NaOH solution
pH > 10.0
Specific activity No carrier added
Radioactivity concentration > 740 MBq/mL
Radionuclidic purity Iodine-124: ≥ 99.5% Iodine-123: < 0.5%
Iodine-125: <0.1%
Iodide-124 > 95% of total activity
Heavy metals Tellurium < 1 µg/mL
Endotoxin < 17.5 IU/mL

When used in PET, 124I seems to have a few inherent disadvantages at first sight. For instance, the isotope emits positrons with a relatively high energy compared to 18F and 89Zr, which would normally have a negative influence on the image resolution. However, the comparisons show that the image quality with 124I only differs marginally from that obtained with other isotopes like 18F and 89Zr. The main reason for this is that state-of-the-art PET scanners dispose of sophisticated hardware and software, so that modern algorithms are able to correct the data and compensate for the higher energy positrons. The end result is a superb combination of simple labeling procedures and the power of high-resolution imaging [3].

Where to buy
Together with our partner PerkinElmer, the distribution of Iodine-124 is reliable, fast and secure. To order this product, visit PerkinElmer’s page on Iodine-124.

(Click on the PMID to see abstracts from PubMed/NCBI)

[1] Koehler L, Gagnon K, McQuarrie S and Wuest F (2010). Iodine-124: a promising positron emitter for organic PET chemistry. Molecules 15: 2686-2718. PMID: 20428073.

[2] Rault E, Vandenberghe S, van Holen R, de Beenhouwer J, Staelens S and Lemahieu I (2007). Comparison of image quality of different iodine isotopes(123I, 124I and 131I). Cancer Biother Radiopharm 22 (3): 423-430. PMID: 17651050.

[3] Belov VV, Bonab AA, Fischman AJ, Heartlein M, Calias P and Papisov MI (2011). Iodine-124 as a label for pharmacological PET imaging. Mol Pharmaceutics 8: 736-747. PMID: 21361362.

Further reading suggestions
(Click on the PMID to see abstracts from PubMed/NCBI)

Kemerink GJ, Visser MG, Franssen R, Beijer E, Zamburlini M, Halders SG, Brans B, Mottaghy FM, Teule GJ. Effect of the positron range of 18F, 68Ga and 124I on PET/ CT in lung-equivalent materials. Eur J Nucl Med Mol Imaging. 2011 May;38(5):940-8. PMID: 21287170.

Lopci E, Chiti A, Castellani MR, Pepe G, Antunovic L, Fanti S, Bombardieri E. Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S28-40. PMID: 21484381.

Lubberink M, Herzog H. Quantitative imaging of 124I and 86Y with PET. Eur J Nucl Med Mol Imag- ing. 2011 May;38 Suppl 1:S10-8. PMID: 21484385.

Pryma DA, O’Donoghue JA, Humm JL, Jungbluth AA, Old LJ, Larson SM, Divgi CR. Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250. J Nucl Med. 2011 Apr;52(4):535-40. PMID: 21421715.

Schmitz J. The production of 124I iodine and 86Y yttrium. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S4-9. PMID: 21484376.

Tijink BM, Perk LR, Budde M, Stigter-van Walsum M, Visser GWM, Kloet RW, Dinkelborg LM, Leemans CR, Neri D, van Dongen GAMS. 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging. 2009 Aug;36(8):1235-44. PMID: 19259661.

Visser GW, Klok RP, Gebbinck JW, ter Linden T, van Dongen GA, Molthoff CF. Optimal quality 131I- monoclonal antibodies on highdose labeling in a large reaction volume and temporarily coating the antibody with IODOGEN. J Nucl Med. 2001 Mar;42(3):509-19. PubMed PMID: 11337531.

BV Cyclotron VU is a global health science company that produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Located at the campus of VU University Medical Center in Amsterdam, BV Cyclotron VU produces GMP-compliant medical isotopes in state-of-the-art manufacturing facilities. They are used daily by pharmaceutical and biotechnological companies, medical device manufacturers, hospitals, clinics, and research laboratories.
Order our products directly from one of our distribution partners.